Theophylline (DrugBank: Theophylline)
2 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 236 | 偽性副甲状腺機能低下症 | 5 |
| 299 | 嚢胞性線維症 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04551170 (ClinicalTrials.gov) | July 13, 2020 | 9/9/2020 | Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old | Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism | Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1a | Drug: Theophylline;Drug: Placebo | Vanderbilt University Medical Center | NULL | Recruiting | 2 Years | 12 Years | All | 34 | Phase 2 | United States |
| 2 | NCT04240821 (ClinicalTrials.gov) | May 22, 2020 | 21/1/2020 | Theophylline for Treatment of Pseudohypoparathyroidism | Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism | Pseudohypoparathyroidism;Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy | Drug: Theophylline ER | Ashley Shoemaker | NULL | Enrolling by invitation | 2 Years | 99 Years | All | 34 | Phase 2 | United States |
| 3 | NCT03718403 (ClinicalTrials.gov) | April 10, 2019 | 8/9/2017 | Effect of Theophylline in Pseudohypoparathyroidism | Effect of Theophylline in Pseudohypoparathyroidism | PHP Ia;PHP IB;Php1C | Drug: Theophylline | Massachusetts General Hospital | NULL | Not yet recruiting | 5 Years | 21 Years | All | 40 | Phase 4 | NULL |
| 4 | NCT03029429 (ClinicalTrials.gov) | September 1, 2018 | 18/1/2017 | Theophylline Treatment for Pseudohypoparathyroidism | Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism | Pseudohypoparathyroidism;Albright Hereditary Osteodystrophy | Drug: Theophylline;Drug: Placebos | Vanderbilt University Medical Center | Harvard University | Recruiting | 13 Years | 99 Years | All | 34 | Phase 2 | United States |
| 5 | NCT02463409 (ClinicalTrials.gov) | June 2015 | 20/5/2015 | Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy) | Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a | Pseudohypoparathyroidism Type 1a;Albright Hereditary Osteodystrophy | Drug: Theophylline | Vanderbilt University Medical Center | Massachusetts General Hospital | Completed | 10 Years | 21 Years | All | 6 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01684683 (ClinicalTrials.gov) | November 2012 | 11/9/2012 | The Effect of Theophylline in the Treatment of Bronchiectasis | Clinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) Bronchiectasis | Bronchiectasis | Drug: Theophylline;Drug: Placebo(for Theophylline) | The First Affiliated Hospital of Guangzhou Medical University | NULL | Completed | 18 Years | 70 Years | Both | 100 | Phase 4 | China |
| 2 | ChiCTR-TRC-12002470 | 2012-09-15 | 2012-08-02 | The effect of theophylline in the treatment of bronchiectasis, a random, double blind study | The effect of theophylline in the treatment of bronchiectasis, a random, double blind study. | bronchiectasis not due to cystic fibrosis | 1:theophylline;2:theophylline; | The first affiliated hospital of Guangzhou Medical University | NULL | Completed | 15 | 65 | Both | 1:46;2:46; | China |